Tag Archives: atrial fibrillation

Highlights TCT 2019

TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

Courtesy of SBHCI. The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation admitted with acute coronary syndrome (who receive medical treatment or angioplasty) may vary from that in patients undergoing elective treatment. At 14 days from elective angioplasty or hospitalization due to acute coronary syndrome, patients were randomized in a 2×2

Efectos de la radiación cerebral en Cardiólogos Intervencionistas

Heart and Brain: Risk Factors, Atrial Fibrillation and Dementia

For decades, physiologists have known what cardiologists often forget: heart and brain communicate intensely in a healthy person, and in a wide range of cardiovascular diseases they could damage one another. Multiple actions and immediate reactions in the brain adequately adapt heart function to bodily needs, such as anxiety and frustration, which might impair adequate

Mejoras tecnológicas en las válvulas que se traducen en resultados clínicos

New Percutaneous Devices to Prevent Embolism in Atrial Fibrillation

Patients with atrial fibrillation (AF) unsuitable for anticoagulation because of bleeding risk, require other strategies to prevent stroke. For some years, there have been in the market (limited to some places; not as part of the regular agenda of cardiologists and hematologists) devices to occlude the atrium that have been proved safe and effective. These

TCT 2018 | OAC-ALONE: solo anticoagulación luego del año de un stent en pacientes fibrilados

TCT 2018 | OAC-ALONE: Anticoagulation Alone 1 Year After Stenting in Patients with Atrial Fibrillation

Up to now, there had been no randomized controlled trial assessing oral anticoagulation alone vs. oral anticoagulation plus antiplatelet therapy in patients with atrial fibrillation 1 year after stenting in a setting of stable coronary disease. Such was the vacuum that this work, presented at TCT 2018 and published simultaneously in Circulation, attempted to fill. This trial

AINES y riesgo de sangrado en pacientes con fibrilación auricular

NSAIDs and Risk of Bleeding in Patients with Atrial Fibrillation

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is very frequent and many of these medications are sold over-the-counter, but they can expose patients with atrial fibrillation using warfarin or dabigatran to potentially dangerous bleeding. Such a combination is a “perfect storm” of sorts, since atrial fibrillation is the most frequent type of arrhythmia and its

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

The End of Aspirin for Anticoagulated Patients Undergoing PCI

The discussion about the best anti-thrombotic strategy for patients with atrial fibrillation undergoing PCI seemed never-ending until the RE-DUAL PCI trial was published in the New England Journal of Medicine (NEJM). This study has arrived to simplify the tough choice between the risk of a thrombotic event vs. the risk of bleeding with a simpler scheme, without

TCT 2017 | Resultados finales del dispositivo Watchman

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

Courtesy of SBHCI. The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke prevention rate to that of warfarin, though with a clear reduction in bleeding. The meta-analysis showed a significant reduction in hemorrhagic stroke (0.17% vs 0.87%), non-procedure related

RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI

RE-DUAL PCI outcomes have been published by the  New England Journal of Medicine along with their presentation at ESC 2017. The traditional triple anti-thrombotic scheme with dual antiplatelet therapy  and warfarin for patients with atrial fibrillation undergoing coronary angioplasty seems to have been left behind.   This new study showed that the combination of dabigatran with a P2Y12

Trombólisis local en tromboembolismo pulmonar

Diastolic Dysfunction: Shall We Begin to Assess It?

Courtesy of Dr. Carlos Fava. The association between diastolic dysfunction (DD) and aortic insufficiency (AI) after transcatheter aortic valve replacement (TAVR) has not been studied yet, but the presence of aortic regurgitation has proved to be associated with worse outcomes.   A total of 144 out of 195 patients who underwent TAVR with balloon-expandable SAPIENS or SAPIENS XT

oclusion de orejuela durante cirugia

Closing off the Appendage While Performing Cardiac Surgery Results in a Reduction in Risk of Embolic Stroke

Closing off the left appendage as an add-on procedure while performing other cardiac surgery in patients with atrial fibrillation resulted in a reduction in risk of embolic stroke of nearly 40% over 12 months, according to an analysis carried out on the Society of Thoracic Surgeons (STS) database.   Patients who had surgical appendage occlusion had